GOLIMUMAB SAFETY ACCORDING TO CLINICAL FINDINGS
https://doi.org/10.14412/1995-4484-2015-200-204
Abstract
The review analyzes trials dealing with the safety of golimumab (GLM) used in rheumatology. This drug was the latest
Contact: Galina Lukina;
Поступила 12.05.14
tumor necrosis factor α (TNF-α) inhibitor introduced into clinical practice and therefore the estimation of its tolerability is particularly relevant. The data obtained in large-scale clinical trials suggest that GLM has a good safety profile. The most common adverse events (AE) were infections, more often mild. The rate of infections was higher with the use of GLM 100 mg than with that of 50 mg. The overall cancer rate did not increase during a follow-up of less than 160 weeks. However, the rate of lymphomas in patients receiving GLM 100 mg proved to be higher than in those taking GLM 50 mg, in the general population, and in the placebo group in particular. AE were evenly distributed among patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Overall, the findings are in agreement with the data on the safety of previously used TNF-α inhibitors. No fundamentally new AE have been encountered. It is necessary to accumulate data on the use of GLM in real clinical practice, which will be able to more objectively define its place in the current therapy of rheumatic diseases.
About the Authors
G. V. Lukina
V.A. Nasonova Research Institute of Rheumatology, Moscow
Russian Federation
Russian Federation
Ya. A. Sigidin
V.A. Nasonova Research Institute of Rheumatology, Moscow
Russian Federation
Russian Federation
Contact: Galina Lukina; gvl3@yandex.ru
References
1. Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370:1861–74. doi: 10.1016/S0140-6736(07)60784-3
2. Насонов ЕЛ. Перспективы лечения ревматических заболеваний в начале 21 века. Терапевтический архив. 2011;(5):5–9. [Nasonov EL. Prospects for treatment of rheumatic diseases in the early 21st century. Terapevticheskii arkhiv. 2011;(5):5–9. (In Russ.)].
3. Feldman M, Maini RN. Role of cytokines in rheumatoid arthritis: an education in pathophysiology ant therapeutics. Immunol Rev. 2008;223:7–19. doi: 10.1111/j.1600-065X.2008.00626.x
4. Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol. 2010;10:308–15. doi: 10.1016/j.coph.2010.01.005
5. Насонов ЕЛ. Место голимумаба при ревматоидном артрите. Научно-практическая ревматология. 2012;51(Прил. 3):2–10. [Nasonov EL. Place of golimumab in rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;51(Прил. 3):2–10. (In Russ.)].
6. Эрдес ШФ. Применение голимумаба при анкилозирующем спондилите. Научно-практическая ревматология. 2012;51(Прил. 3):11–6. [Erdes ShF. The use of golimumab in ankylosing spondylitis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;51(Прил. 3):11–6. (In Russ.)].
7. Коротаева ТВ. Результаты оценки эффективности и безопасности голимумаба — нового ингибитора фактора некроза опухоли альфа в лечении псориатического артрита. Научно-практическая ревматология. 2012;51(Прил. 3):17–22. [Korotaeva TV. The results of evaluation of the effectiveness and safety of golimumab – new inhibitor of tumor necrosis factor Alfa treatment of psoriatic arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;51(Прил. 3):17–22. (In Russ.)].
8. Beevor CP, Hull R, Thomas A, et al. Anti TNFa therapy reduce emergency health services usage. Ann Rheum Dis. 2006;65 Suppl II:176.
9. Gomez-Reino JJ, Dasgupta B, Haugeberg G, et al. Mortality rate is reduced in RA patients treated with TNF antagonists. Data from Biobadaser. Ann Rheum Dis. 2006;65 Suppl II:318.
10. Abbott Laboratories. Humira (adalimumab) [highlights of prescribing information]. Last revised September 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/12505 7s232lbl.pdf (accessed 17 Apr 2013).
11. UCB Inc. Cimzia (certolizumab) [highlights of prescribing information]. Last revised November 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/12516 0s189lbl.pdf (accessed 17 Apr 2013).
12. Amgen Wyeth, manufactured by Immunex. Enbrel (etanercept) [highlights of prescribing information]. Last revised December 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103795s5507lbl.pdf (accessed 17 Apr 2013).
13. Janssen Biotech, Inc. Remicade (infliximab) [highlights of prescribing information]. Last revised March 2013. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103772s5345lbl.pdf (accessed 17 Apr 2013).
14. Zhou H, Xu Z, Rahman MU, et al. Exposure-efficacy assessment of golimumab in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2006;65:514.
15. Smolen J, Kay J, Doyle MK, et al. Golimumab, a new human anti-TNF-alpha monoclonal antibody. Ann Rheum Dis. 2008;67 Suppl II:50–1.
16. Keystone E, Genovese MC, Klareskog L, et al. Golimumab, a new human anti-TNF-alpha monoclonal antibody. Ann Rheum Dis. 2009;68:789–96. doi: 10.1136/ard.2008.099010
17. Kay J, Fleischmann R, Keystone E, et al. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis. Published Online First: doi: 10.1136/ annrheumdis-2013-204195
18. Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis wth tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48:2122–7. doi: 10.1002/art.11137
19. Насонов ЕЛ, Козлов РС, Якушин СБ. Инфекционные осложнения терапии блокаторами фактора некроза опухоли: предупрежден – значит вооружен. Клиническая микробиология и антимикробная химиотерапия.
20. ;(4):1–11. [Nasonov EL, Kozlov RS, Yakushin SB. Infectious complications of therapy of tumor necrosis factor blockers: forewarned – is forearmed. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2006;(4):1–11. (In Russ.)].
21. Furst DE, Keystone EC, Fleischmann R, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis. 2010;69 Suppl:i2–29. doi: 10.1136/ard.2009.123885
22. Cellestis. QuantiFERON-TB Gold clinicians guide and QuantiFERON-TB Gold In-Tube method package insert. Available from: www.cellestis.com
23. Oxford Immunotec. T-SPOT.TB. Available from: http://www.oxford immunotec.com/T-SPOT_International
24. Hsia E, Cush J, Eric L, et al. Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in phase III clinical trials. Arthritis Care Res. 2013 Feb;65(2):309–13. doi: 10.1002/acr.21788
25. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al.; on behalf of the BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005;52:1766–72. doi: 10.1002/art.21043
26. Available from: www.who.int/tb/country/data/download/en/index.html
27. Janssen Biotech, Inc. Simponi (golimumab) [highlights of prescribing information]. Last revised November 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125289s070lbl.pdf (accessed 17 Apr 2013).
28. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;2:CD008794. doi: 10.1002/14651858.CD008794.pub2
29. Kay J, Rahman MU. Golimumab: A novel human anti-TNFalpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Core Evid. 2010;4:159–70.
Review
For citations:
Lukina G.V., Sigidin Ya.A. GOLIMUMAB SAFETY ACCORDING TO CLINICAL FINDINGS. Rheumatology Science and Practice. 2015;53(2):200-204. (In Russ.) https://doi.org/10.14412/1995-4484-2015-200-204
Views:
924
Email this article 